BACKGROUND AND PURPOSE: Oestrogen loss at menopause is frequently related to poor wound healing. Genistein has been tested in anti-ageing cosmetic preparations with interesting results on skin health. Here, we investigated the effects of the genistein aglycones, given systemically, in an incisional model of wound healing, compared to systemic oestradiol and raloxifene. EXPERIMENTAL APPROACH: Six months after ovariectomy (OVX), rats were randomly assigned to groups of 12 animals each and treated daily with genistein aglycone (1 and 10 mg kg(-1) s.c.), raloxifene hydrochloride (0.05 and 0.5 mg kg(-1) s.c.) or 17-alpha-ethinyl oestradiol (0.003 and 0.03 mg kg(-1) s.c.) for 12 weeks. Untreated OVX and sham OVX rats were used as controls. Then, 14 or 7 days before the end of the experiment, an incisional wound healing procedure was performed and skin specimens were collected to evaluate molecular, histological and functional measurements. KEY RESULTS: Seven and fourteen days after wounding, samples from OVX rats showed a decrease in transforming growth factor-beta1, tissue transglutaminase 2 and vascular endothelial growth factor compared to samples from sham OVX rats. Oestradiol, raloxifene and genistein all significantly modified this decrease, but the lowest genistein dose exerted a greater effect than the other treatments. Moreover, the lowest dose of genistein was the most effective in improving skin healing and wound tensile strength. CONCLUSIONS AND IMPLICATIONS: Genistein aglycone might be an alternative therapy for the management of skin wound healing.
BACKGROUND AND PURPOSE: Oestrogen loss at menopause is frequently related to poor wound healing. Genistein has been tested in anti-ageing cosmetic preparations with interesting results on skin health. Here, we investigated the effects of the genistein aglycones, given systemically, in an incisional model of wound healing, compared to systemic oestradiol and raloxifene. EXPERIMENTAL APPROACH: Six months after ovariectomy (OVX), rats were randomly assigned to groups of 12 animals each and treated daily with genistein aglycone (1 and 10 mg kg(-1) s.c.), raloxifene hydrochloride (0.05 and 0.5 mg kg(-1) s.c.) or 17-alpha-ethinyl oestradiol (0.003 and 0.03 mg kg(-1) s.c.) for 12 weeks. Untreated OVX and sham OVX rats were used as controls. Then, 14 or 7 days before the end of the experiment, an incisional wound healing procedure was performed and skin specimens were collected to evaluate molecular, histological and functional measurements. KEY RESULTS: Seven and fourteen days after wounding, samples from OVX rats showed a decrease in transforming growth factor-beta1, tissue transglutaminase 2 and vascular endothelial growth factor compared to samples from sham OVX rats. Oestradiol, raloxifene and genistein all significantly modified this decrease, but the lowest genistein dose exerted a greater effect than the other treatments. Moreover, the lowest dose of genistein was the most effective in improving skin healing and wound tensile strength. CONCLUSIONS AND IMPLICATIONS: Genistein aglycone might be an alternative therapy for the management of skin wound healing.
Authors: Robert W Hsieh; Shyamala S Rajan; Sanjay K Sharma; Yuee Guo; Eugene R DeSombre; Milan Mrksich; Geoffrey L Greene Journal: J Biol Chem Date: 2006-04-28 Impact factor: 5.157
Authors: S Mäkelä; H Savolainen; E Aavik; M Myllärniemi; L Strauss; E Taskinen; J A Gustafsson; P Häyry Journal: Proc Natl Acad Sci U S A Date: 1999-06-08 Impact factor: 11.205
Authors: M J Thornton; A H Taylor; K Mulligan; F Al-Azzawi; C C Lyon; J O'Driscoll; A G Messenger Journal: Exp Dermatol Date: 2003-04 Impact factor: 3.960
Authors: H Marini; A Bitto; D Altavilla; B P Burnett; F Polito; V Di Stefano; L Minutoli; M Atteritano; R M Levy; N Frisina; S Mazzaferro; A Frisina; R D'Anna; F Cancellieri; M L Cannata; F Corrado; C Lubrano; R Marini; E B Adamo; F Squadrito Journal: Nutr Metab Cardiovasc Dis Date: 2009-07-23 Impact factor: 4.222
Authors: G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson Journal: Endocrinology Date: 1998-10 Impact factor: 4.736
Authors: Tírcia C Santos; Bernhard Höring; Kathrin Reise; Alexandra P Marques; Simone S Silva; Joaquim M Oliveira; João F Mano; António G Castro; Rui L Reis; Martijn van Griensven Journal: Tissue Eng Part A Date: 2013-02-19 Impact factor: 3.845
Authors: Seungkuk Ahn; Christophe O Chantre; Alanna R Gannon; Johan U Lind; Patrick H Campbell; Thomas Grevesse; Blakely B O'Connor; Kevin Kit Parker Journal: Adv Healthc Mater Date: 2018-01-23 Impact factor: 9.933
Authors: David M Ansell; Laura Campbell; Helen A Thomason; Andrew Brass; Matthew J Hardman Journal: Wound Repair Regen Date: 2014 Mar-Apr Impact factor: 3.617
Authors: Lenka Fáber; Ivan Kováč; Petra Mitrengová; Martin Novotný; Lenka Varinská; Tomáš Vasilenko; Martin Kello; Matúš Čoma; Tomáš Kuruc; Klaudia Petrová; Ivana Miláčková; Anika Kuczmannová; Vlasta Peržeľová; Štefánia Mižáková; Erik Dosedla; František Sabol; Ján Luczy; Milan Nagy; Jaroslav Majerník; Martin Koščo; Pavel Mučaji; Peter Gál Journal: Molecules Date: 2018-07-04 Impact factor: 4.411